↓ Skip to main content

Anthelmintics for people with neurocysticercosis.

Overview of attention for article published in Cochrane database of systematic reviews, March 2010
Altmetric Badge

Citations

dimensions_citation
28 Dimensions

Readers on

mendeley
57 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Anthelmintics for people with neurocysticercosis.
Published in
Cochrane database of systematic reviews, March 2010
DOI 10.1002/14651858.cd000215.pub4
Pubmed ID
Authors

Katharine Abba, Sridharan Ramaratnam, Lakshmi Narasimhan Ranganathan, Cochrane Infectious Diseases Group

Abstract

Neurocysticercosis is an infection of the brain by the larval stage of the pork tapeworm. In endemic areas it is a common cause of epilepsy. Anthelmintics (albendazole or praziquantel) may be given to kill the parasites. However, there are potential adverse effects, and the parasites may eventually die without treatment. To assess the effectiveness and safety of anthelmintics for people with neurocysticercosis. In May 2009 we searched the Cochrane Infectious Diseases Group Specialized Register, CENTRAL (The Cochrane Library 2009, Issue 2), MEDLINE, EMBASE, LILACS, and the mRCT. Randomized controlled trials comparing anthelmintics with placebo, no anthelmintic, or other anthelmintic regimen for people with neurocysticercosis. Two authors independently selected trials, extracted data, and assessed each trial's risk of bias. We calculated risk ratios (RR) for dichotomous variables, with 95% confidence intervals (CI). We pooled data from trials with similar interventions and outcomes. For viable lesions in children, there were no trials. For viable lesions in adults, no difference was detected for albendazole compared with no treatment for recurrence of seizures (116 participants, one trial); but fewer participants with albendazole had lesions at follow up (RR 0.56, 95% CI 0.45 to 0.70; 192 participants, two trials).For non-viable lesions in children, seizures recurrence was less common with albendazole compared with no treatment (RR 0.49, 95% CI 0.32 to 0.75; 329 participants, four trials). There was no difference detected in the persistence of lesions at follow up (570 participants, six trials). For non-viable lesions in adults, there were no trials.In trials including viable, non-viable or mixed lesions (in both children and adults), headaches were more common with albendazole alone (RR 9.49, 95% CI 1.40 to 64.45; 106 participants, two trials), but no difference was detected in one trial giving albendazole with corticosteroids (116 participants, one trial). In patients with viable lesions, evidence from trials of adults suggests albendazole may reduce the number of lesions. In trials of non-viable lesions, seizure recurrence was substantially lower with albendazole, which is counter-intuitive. It may be that steroids influence headache during treatment, but further research is needed to test this.

Mendeley readers

The data shown below were compiled from readership statistics for 57 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Ecuador 1 2%
Brazil 1 2%
Unknown 55 96%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 8 14%
Student > Master 8 14%
Student > Ph. D. Student 7 12%
Other 6 11%
Researcher 6 11%
Other 13 23%
Unknown 9 16%
Readers by discipline Count As %
Medicine and Dentistry 22 39%
Nursing and Health Professions 7 12%
Pharmacology, Toxicology and Pharmaceutical Science 3 5%
Biochemistry, Genetics and Molecular Biology 2 4%
Social Sciences 2 4%
Other 7 12%
Unknown 14 25%